5 quarters tracked · Beat rate 100% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.76 | $3.02 | +9.2% | Beat |
| Q1 2026 | 2026-03-31 | $1.96 | $2.06 | +5.0% | Beat |
| Q4 2025 | 2025-12-31 | $2.37 | $2.39 | +1.0% | Beat |
| Q3 2025 | 2025-09-30 | $2.36 | $2.43 | +2.9% | Beat |
| Q2 2025 | 2025-06-30 | $2.52 | $3.12 | +23.7% | Beat |
Earnings Beat Rate
Charles River Laboratories has beaten analyst EPS estimates in 5 of 5 tracked quarters (100% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →